Novo Nordisk has found itself in an increasingly chaotic situation as of late, with shares plunging and investor confidence ...

More than half the board of directors, including the chair, will be removed through Friday’s extraordinary general meeting ...

Novo Nordisk faces a shareholder backlash on Friday as the Danish drugmaker's minority investors prepare a protest vote ...

Signed, sealed and delivered, Metsera is finally Pfizer’s. Pfizer has completed its acquisition of the obesity biotech, ...

Novo Nordisk's CEO Mike Doustdar made a daring $10 billion bid for Metsera to assert dominance in the obesity drugs market, ...

Mikael Dolsten, Pfizer's former research and development chief, has withdrawn his candidacy for Novo Nordisk's board, citing ...

Oliver Barnes Pfizer and Novo Nordisk duked it out for who will own Metsera — a coveted biotech that’s developing ...

Novo Nordisk and Eli Lilly deny partnership with Mangoceuticals for weight-loss drugs, causing Mangoceuticals' shares to ...

Korro Bio Shares plummeted after the company agreed with Novo Nordisk to pause the companies' license agreement and research collaboration and said it would cut 34% of its workforce. The stock fell 79 ...

Novo Nordisk has reported the mixed midphase results behind its push to enter a heart disease market s | Novo Nordisk has reported the mixed midphase results behind its push to enter a heart disease ...

Major U.S. indices closed mixed on Tuesday, with the Dow Jones Industrial Average climbing 1.2% to 47,927.96 and the S&P 500 ...

Novo Nordisk A/S is tapping the euro bond market with a multi-tranche sale expected to raise about €3.5 billion ($4.1 billion ...